

[Bloomberg.com](#)  
[Businessweek.com](#)  
[Bloomberg TV](#)  
 Premium

- [Professional Products](#)
- [Bloomberg Anywhere](#)
- [Bloomberg Tradebook](#)

#### Industry Products

- [Bloomberg Briefs](#)
- [Bloomberg Government](#)
- [Bloomberg Law](#)
- [Bloomberg BNA](#)
- [Bloomberg New Energy Finance](#)
- [Bloomberg Sports](#)

#### Enterprise Products

- [Compliance Solutions](#)
- [Data Solutions](#)
- [Technology Solutions](#)
- [Trading Solutions](#)
- [Register](#)
- [Sign In](#)

#### Market Snapshot

- U.S.
- Europe
- Asia

Ticker	Volume	Price	Price Delta
<a href="#">DJIA</a>	18,135.53	15.75	0.09%
<a href="#">S&amp;P 500</a>	2,122.56	-0.29	-0.01%
<a href="#">NASDAQ</a>	5,154.28	0.31	0.01%

Ticker	Volume	Price	Price Delta
<a href="#">STOXX 50</a>	3,625.97	29.90	0.83%
<a href="#">FTSE 100</a>	6,834.87	9.20	0.13%
<a href="#">DAX</a>	11,542.54	82.04	0.72%

Ticker	Volume	Price	Price Delta
<a href="#">NIKKEI</a>	20,809.42	381.23	1.87%
<a href="#">TOPIX</a>	1,676.40	27.79	1.69%
<a href="#">HANG SENG</a>	27,333.46	252.61	0.93%



CUSTOMER CARE

**Customer Care and social media: the next generation**

How Customer Care is harnessing the power of machine learning.



[See the Slideshare](#)

[Bloomberg](#)

- [Our Company](#)

- [Professional](#)
- [Anywhere](#)

Search News, Quotes and O

- [Home](#)
  - [Bloomberg Homepage](#)
  - [More](#)
  - [Mobile Apps](#)
  - [Businessweek.com](#)
  - [Insights Series](#)
  - [Bloomberg Blog](#)
- [Quick](#)
- [News](#)
  - [Top Headlines](#)
  - [Most Popular](#)
  - [Exclusive](#)
  - [Law](#)
  - [Entrepreneurs](#)
  - [Leaders](#)
  - [Arts & Culture](#)
  - [Economy](#)
  - [Environment](#)
  - [Science](#)
  - [Sports](#)
  - [Markets Magazine](#)
  - [Regions](#)
    - [U.S.](#)
    - [China](#)
    - [Europe](#)
    - [Asia](#)
    - [U.K. & Ireland](#)
    - [Australia & New Zealand](#)
    - [Canada](#)
    - [India & Pakistan](#)
    - [Japan](#)
    - [Africa](#)
    - [Eastern Europe](#)
    - [More Regions](#)
  - [Markets](#)
    - [Commodities](#)
    - [Currencies](#)
    - [Bonds](#)
    - [Stocks](#)
    - [Energy Markets](#)
    - [Municipal Bonds](#)
    - [Emerging Markets](#)
    - [Funds](#)
    - [Islamic Finance](#)
    - [More Markets](#)
  - [Industries](#)
    - [Energy](#)
    - [Technology](#)
    - [Real Estate](#)

- [Finance](#)
- [Health Care](#)
- [Transportation](#)
- [Insurance](#)
- [Retail](#)
- [Media](#)
- [More Industries](#)
- [Opinion](#)
  - [Editorials](#)
  - [Columns](#)
  - [Op-Eds](#)
  - [Business Class](#)
  - [Echoes](#)
  - [The Ticker](#)
  - [World View](#)
- [Market Data](#)
  - [Stocks](#)
    - [Stock Futures](#)
    - [World Indexes](#)
    - [Gainers & Losers](#)
    - [Regional Indexes](#)
    - [Earnings](#)
  - [Rates & Bonds](#)
    - [Government Bonds](#)
    - [Corporate Bonds](#)
    - [Key Rates](#)
  - [Commodities](#)
    - [Commodity Futures](#)
    - [Energy Prices](#)
  - [Currencies](#)
    - [World Currencies](#)
    - [Foreign Exchange Rates](#)
  - [ETFs](#)
  - [Mutual Funds](#)
  - [Economic Calendar](#)
  - [Forex Trading Videos](#)
- [Personal Finance](#)
  - [Overview](#)
    - [Saving & Investing](#)
    - [Real Estate](#)
    - [Retirement Planning](#)
    - [Financial Advisers](#)
    - [Taxes](#)
    - [Real Cost Of](#)
    - [Money Gallery](#)
    - [Insurance & Health](#)
    - [Portfolio Impact](#)
    - [Calculators](#)
    - [Portfolio Tracker](#)
- [Tech](#)
  - [Overview](#)
    - [Social Media](#)
    - [Mobile & Wireless](#)
    - [Web](#)

- [Enterprise Tech](#)
- [TV, Games & Movies](#)
- [Apple](#)
- [Tech Deals](#)
- [Tech Blog](#)
- [Slideshows](#)
- [Videos](#)
- [Politics](#)
  - [Overview](#)
    - [Elections](#)
    - [White House](#)
    - [Congress](#)
    - [State & Local](#)
    - [Political Capital](#)
    - [Videos](#)
    - [Live Blogs](#)
- [Sustainability](#)
  - [Overview](#)
    - [Energy](#)
    - [Corporate Sustainability](#)
    - [Policy](#)
    - [Natural Resources](#)
    - [Health & Population](#)
    - [Slideshows](#)
    - [Videos](#)
    - [Blog: The Grid](#)
- [TV](#)
  - [Live TV](#)
  - [Channel Finder](#)
  - [Personalities](#)
  - [iPad App](#)
  - [Schedule](#)
    - [U.S.](#)
    - [Asia](#)
    - [Europe](#)
  - [Shows](#)
    - [Surveillance](#)
    - [Market Makers](#)
    - [Lunch Money](#)
    - [Street Smart](#)
    - [Bloomberg West](#)
    - [Game Changers](#)
    - [More Shows](#)
- [Video](#)
  - [Must See](#)
  - [Latest](#)
  - [Most Watched](#)
  - [Interviews](#)
- [Radio](#)
  - [Live Radio](#)
  - [Shows](#)
  - [Schedule](#)
  - [Personalities](#)
  - [Podcasts](#)

- [First Word](#)
- [Surveillance](#)
- [Taking Stock](#)
- [More Podcasts](#)

## ISTA Pharmaceuticals Announces XIBROM(TM) Shipments to

ISTA Pharmaceuticals Announces XIBROM(TM) Shipments to Wholesalers to End on February 28, 2011

BROMDAY(TM) Launch On Track -- Capturing 46% of Weekly New Prescriptions in the Bromfenac Franchise by the End of January

IRVINE, CA -- (Marketwire) -- 02/08/11 -- ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced that due to the rapid adoption of BROMDAY(TM) (bromfenac ophthalmic solution) 0.09%, the first and only once-daily non-steroidal anti-inflammatory (NSAID) prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction, the company will stop selling twice-daily XIBROM (bromfenac ophthalmic solution)(R) 0.09%. ISTA no longer plans to supply XIBROM to pharmaceutical wholesalers after February 28, 2011. For approximately 2-3 weeks thereafter, there will be a limited supply of XIBROM available at wholesalers and pharmacies to fill remaining XIBROM prescriptions. ISTA anticipates wholesalers will continue to sell XIBROM to pharmacies until their inventory is depleted.

As of Fall of 2010, according to data from IMS, twice-daily XIBROM (bromfenac ophthalmic solution)(R) 0.09% had become the most prescribed branded ocular NSAID in the U.S. market for use following cataract surgery. Last October, ISTA received U.S. Food and Drug Administration (FDA) approval for BROMDAY(TM), a once-daily formulation of bromfenac. BROMDAY has been granted three years of marketing exclusivity as provided under the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act. Under the Hatch-Waxman Act, the FDA may not approve an Abbreviated New Drug Application for a generic version of BROMDAY until October 2013. ISTA launched BROMDAY at the end of November 2010 and, since that time, has focused most of the sales team's efforts on converting physicians who prescribed XIBROM to prescribing BROMDAY.

"The transition to BROMDAY has been swift. As of the last week in January, 46% of the XIBROM new prescriptions have been converted over to BROMDAY, according to weekly prescription data supplied by IMS," stated Vicente Anido, Jr., PhD, President and Chief Executive Officer of ISTA Pharmaceuticals. "Having the first and only once-a-day NSAID for postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction has proven to be a major differentiation in the eyes of our customers and their patients. We look forward to gaining even wider acceptance of BROMDAY throughout the prescribing ophthalmic community in the years to come."

**ABOUT ISTA PHARMACEUTICALS** ISTA Pharmaceuticals, Inc., is the fourth largest and fastest growing branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics. ISTA currently markets five products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The company's development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain and nasal allergies. Headquartered in Irvine, California, the company generated 2009 revenues of \$111 million. For additional information about ISTA Pharmaceuticals, please visit the corporate website at [www.istavision.com](http://www.istavision.com).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.